Navigation Links
Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
Date:10/8/2009

LAKE FOREST, Ill., Oct. 8 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today signed a Business Cooperation Agreement with South Korea-based Celltrion, Inc. and Celltrion Healthcare, Inc. ("Celltrion"), which outlines the business terms of a future distribution agreement for the United States, Europe, Australia, New Zealand and Canada for eight biogeneric products that are currently under development by Celltrion, five of which are incremental to Hospira's pipeline. Under the distribution agreement, the parties would collaborate on manufacturing and supply of the products. After regulatory approval, Hospira and Celltrion would co-exclusively market the drugs, with the products independently commercialized under each party's brand name.

"Celltrion brings a history of expertise in the manufacturing of protein-based therapeutics," said Christopher B. Begley, chairman and chief executive officer, Hospira. "This partnership gives Hospira access to Celltrion's large biogenerics portfolio, and is an excellent example of Hospira's commitment to organic and inorganic growth. We're excited to work with Celltrion, and we look forward to expanding Hospira's presence in these significant biogenerics markets."

"Hospira is the world leader in generic injectable pharmaceuticals and has the capabilities and experience to successfully sell biogenerics in these important markets," said Jung-Sin Seo, CEO and chairman, Celltrion Healthcare, Inc. and Celltrion, Inc. "We believe this partnership will benefit both companies by combining Hospira's broad outreach with Celltrion's advanced biologic manufacturing capabilities."

Financial details of the agreement were not disclosed. The Business Cooperation Agreement signed today is expected to lead to a final agreement in the coming months.

About Celltrion

Celltrion, Inc. is a leading biopharmaceutical company in Korea specializing in monoclonal antibody capabilities to develop, manufacture and distribute biologics that contribute to human life. Based on its world-class technology in monoclonal antibody manufacturing, Celltrion has entered into strategic collaborations with a number of global pharmaceutical companies. In addition, Celltrion is preparing an initiative involving the newly emerging world mAb biosimilar market with its advanced development technology and state-of-the-art facility, and is currently developing a large portfolio of biosimilars of blockbuster biologics.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

                 Private Securities Litigation Reform Act of 1995 --
                   A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding biogenerics and Hospira's goals and strategy. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, and subsequently filed Forms 10-Q, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

SOURCE Hospira, Inc.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Chris Jensen Medical Center Saves Estimated $600,000 in First Year of Safe Patient Handling
2. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
3. Two Hutchinson Center Scientists Receive a Total of $16.7 Million for Collaborative Stem Cell Research
4. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Intermountain McKay-Dee Hospital Center Expands Real-Time Locating Solution From Versus Technology, Inc.
7. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
8. Michigan Life Science and Innovation Center Opens in Former Pfizer Facility
9. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
10. Clinical Logistics Enters Partnership with Gentris Corporation
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- DaVita Inc. (NYSE: DVA ) today announced ... Net income attributable to DaVita Inc. for ... million, or $0.80 per share and $880 million, or $4.29 ... to DaVita Inc. for the quarter and year ended December ... million, or $0.98 per share, and $789 million, or $3.85 ...
(Date:2/16/2017)... ST. LOUIS , Feb. 16, 2017  Express Scripts (NASDAQ: ... one of the World,s Most Admired Companies within the Health Care: ... to be named one of the World,s Most Admired Companies," said ... is driven by the commitment and passion of our 26,000 employees ... people we serve." ...
(Date:2/16/2017)... , Feb 16, 2017 Research and Markets ... Diagnostics Market Analysis & Trends - Function, Application, Cancer Type, Technology ... ... Cancer Diagnostics Market is poised to grow at a CAGR of ... by 2025. Some of the prominent trends ...
Breaking Medicine Technology:
(Date:2/18/2017)... Aliso Viejo, CA (PRWEB) , ... February 18, ... ... styled animating paragraph presets. Use Pixel Film Studios ’ ProParagraph Fashion ... listings, descriptions, and so many other applications. Users can pick and choose ...
(Date:2/17/2017)... Ocala, FL (PRWEB) , ... February 17, 2017 ... ... of software tools that allow for the electronic prescribing of controlled and non-controlled ... , Ninety percent of pharmacies in the United States now accept electronic ...
(Date:2/17/2017)... ... 17, 2017 , ... Qualis Health, one of the nation's ... Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that ... multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... 2017 , ... PrideStaff, a national staffing organization, is pleased ... Industry Analysts' 2017 "Staffing 100 North America" list. , Now in its ... the staffing industry over the last twelve months. Industry insiders and observers nominate ...
(Date:2/17/2017)... ... 2017 , ... Dillon Ruxton Insurance, a Florida-based agency offering ... the greater Fort Lauderdale metropolitan region, is embarking on a cooperative food drive ... LifeNet 4 Families has provided a broad range of food provision services to ...
Breaking Medicine News(10 mins):